Galmed Pharmaceuticals is a biotechnology business based in the US. Galmed Pharmaceuticals shares (GLMD) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.80 – a decrease of 4.44% over the previous week. Galmed Pharmaceuticals employs 3 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.80 |
|---|---|
| 52-week range | $2.73 - $15.10 |
| 50-day moving average | $4.69 |
| 200-day moving average | $4.24 |
| Wall St. target price | $12.00 |
| PE ratio | 0.0402 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $69.72 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.96 from 2024-11-20
| 1 week (2024-11-15) | 1.02% |
|---|---|
| 1 month (2024-10-23) | -34.80% |
| 3 months (2024-08-22) | 760.47% |
| 6 months (2024-05-22) | 644.65% |
| 1 year (2023-11-22) | 905.78% |
|---|---|
| 2 years (2022-11-22) | -94.88% |
| 3 years (2021-11-22) | 455.4 |
| 5 years (2019-11-22) | 820.8002 |
Valuing Galmed Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Galmed Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Galmed Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Galmed Pharmaceuticals shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -29.31% |
| Return on equity TTM | -52.67% |
| Profit margin | 0% |
| Book value | $33.01 |
| Market Capitalization | $4.6 million |
TTM: trailing 12 months
We're not expecting Galmed Pharmaceuticals to pay a dividend over the next 12 months.
Galmed Pharmaceuticals's shares were split on a 1:12 basis on 29 August 2024 . So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Galmed Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Galmed Pharmaceuticals shares which in turn could have impacted Galmed Pharmaceuticals's share price.
Over the last 12 months, Galmed Pharmaceuticals's shares have ranged in value from as little as $2.73 up to $15.1. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galmed Pharmaceuticals's is 0.798. This would suggest that Galmed Pharmaceuticals's shares are less volatile than average (for this exchange).
Galmed Pharmaceuticals Ltd. , a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.